FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Biblioteca de Peptídeos

Thymalin

Thymaline / Thymic Peptide Extract

Immune & Thymic

Thymalin (also known as Thymic Peptide Extract or Thymalin) is a polypeptide complex extracted from calf thymus glands, developed by Professors Vladimir Khavinson and Vyacheslav Morozov at the St. Petersburg Institute of Bioregulation and Gerontology as an immunomodulatory bioregulator. It was one of the earliest bioregulator peptides investigated for anti-aging applications, with research spanning over 40 years in Russian gerontological medicine. Thymalin is administered via intramuscular injection and targets restoration of thymic function and T-cell immunity that declines with age.

Mecanismo de Ação

Bovine thymus extract containing a mixture of thymic peptide factors. Restores T-cell immunity, promotes thymic regeneration, and modulates immune system homeostasis. Part of the Khavinson bioregulator family targeting the thymus and immune system.

Protocolos de Pesquisa

Para fins de pesquisa apenas. Não é conselhos médicos.

Khavinson protocols use 5-10mg intramuscularly daily for 5-10 day cycles, repeated every 6-12 months. Some protocols use sublingual or oral administration at 10-20mg daily.

Notas de Pesquisa

Clinical Research Status

Thymalin has been studied in longitudinal clinical trials spanning over 15 years in elderly populations, with Khavinson's landmark study demonstrating a 46% reduction in mortality over a 12-year follow-up period in treated versus control groups. It is registered as a pharmaceutical preparation in Russia for immunodeficiency states and as an adjuvant in cancer treatment. While these results are remarkable, they have not been independently replicated in Western research settings or subjected to rigorous international peer review standards.

Key Published Findings

The most cited study showed that combined Thymalin and Epithalon treatment in elderly patients (60-80 years) reduced mortality, improved immune function, and normalized neuroendocrine regulation over 6-12 years of observation. Immunological research demonstrates restoration of T-cell subpopulation ratios, increased natural killer cell activity, and normalization of cytokine profiles in immunocompromised elderly patients. Animal studies in various species show increased lifespan, improved tumor resistance, and restoration of thymic architecture following Thymalin administration.

Safety Profile

Thymalin has been used clinically in Russia for decades with a well-established safety profile showing minimal adverse effects at standard therapeutic doses. The most commonly reported side effects are mild injection site reactions and occasional allergic responses in individuals sensitive to bovine-derived products. As an animal-derived extract, theoretical concerns about prion contamination exist, though no cases have been reported in the published literature.

Comparison to Related Compounds

Thymalin differs from synthetic thymic peptides like Thymosin Alpha-1 (Zadaxin) in that it is a complex mixture of multiple thymic peptides rather than a single defined molecule. Compared to the synthetic thymic dipeptide Thymogen (Glu-Trp), Thymalin contains a broader range of immunoactive components but has less molecular specificity. Thymalin's multi-component nature is considered both an advantage (multiple synergistic mechanisms) and a limitation (difficult to standardize and characterize) compared to single-peptide approaches.

Community Observations

Users in the longevity community often use Thymalin as part of seasonal immune optimization protocols, particularly during winter months or periods of high infection risk. Many combine it with Epithalon in what is sometimes called the "Khavinson protocol" for comprehensive anti-aging effects targeting both immune function and cellular longevity. The requirement for intramuscular injection and limited sourcing options outside Russia present practical barriers for many interested users.

Meio-Vivo

~Variable (mixture)

Reconstituição

Sterile saline or bacteriostatic water for injection

Armazenamento

Liofilizado

Refrigerate 2-8C.

Reconstituído

Use within 24 hours of reconstitution.

Situação Legal nos EUA

Research chemical (approved in Russia)

Também Conhecido Como

ThymalineThymic Peptide Extract

Perguntas frequentes

O que é Thymalin?

Thymalin (also known as Thymic Peptide Extract or Thymalin) is a polypeptide complex extracted from calf thymus glands, developed by Professors Vladimir Khavinson and Vyacheslav Morozov at the St. Petersburg Institute of Bioregulation and Gerontology as an immunomodulatory bioregulator. It was one of the earliest bioregulator peptides investigated for anti-aging applications, with research spanning over 40 years in Russian gerontological medicine. Thymalin is administered via intramuscular injection and targets restoration of thymic function and T-cell immunity that declines with age.

Como Thymalin funciona?

Bovine thymus extract containing a mixture of thymic peptide factors. Restores T-cell immunity, promotes thymic regeneration, and modulates immune system homeostasis. Part of the Khavinson bioregulator family targeting the thymus and immune system.

Qual é o status regulatório de Thymalin nos EUA?

Research chemical (approved in Russia)

Qual é a meia-vida de Thymalin?

~Variable (mixture)

Por quais outros nomes Thymalin é conhecido?

Thymaline, Thymic Peptide Extract

Peptide Contacts fornece resumos baseados em pesquisas apenas para fins informativos. Não hospedamos, distribuímos ou endossamos documentação de fornecedores. Todas as certificações de análise completa, certificados GMP e comunicações de fornecedores devem ser solicitadas e verificadas diretamente pelo comprador. Nada nesta plataforma constitui conselhos legais, médicos ou profissionais. Os usuários são unicamente responsáveis por verificar as credenciais dos fornecedores e garantir a conformidade com todas as leis locais, estaduais e federais aplicáveis antes de adquirir qualquer química de pesquisa. O uso desta plataforma constitui aceitação plena da responsabilidade pessoal.

Leia a declaração completa